Hope for Cancer Patients

Endevica Bio is working hard to develop a treatment for a vexing condition that can have a significant impact on cancer patients but isn’t widely known: cachexia.

It’s a debilitating wasting syndrome that affects up to 80% of people with advanced cancer, according to the National Cancer Institute. Cacexia, which causes dramatic muscle loss, fatigue and a weakened immune system, directly contributes to 30% of cancer deaths.

Cachexia can also affect those with advanced stages of other illnesses, including heart disease, kidney disease and HIV.

For the last decade, Endevica Bio has been working hard to develop a cachexia treatment. Our initial clinical trials show our drug holds significant promise. We expect to enter phase 2 clinical trials by early next year.

Our drug holds significant promise for those suffering from cachexia. Cachexia makes treatment for the underlying illness more difficult. Patients with weakened bodies struggle to tolerate therapies, reducing their effectiveness. Hospital stays lengthen, and healthcare costs soar.

There’s an urgent need for a breakthrough. Current approaches to managing cachexia are limited. We can offer nutritional support and medications to stimulate appetite, but these have mixed results. The lack of targeted therapies is a major gap in our medical arsenal.

A successful treatment for cachexia would be a revolutionary development. It would empower patients to fight their illnesses with renewed strength. It would improve treatment outcomes and reduce healthcare burdens.

Most significantly, a treatment holds the promise of saving lives – and improving the quality of life for the hundreds of thousands of people a year who would otherwise suffer in silence.